Home » Newsletters » BioWorld Science

BioWorld Science

April 15, 2010

View Archived Issues

Promising phase Ib data on TD-101 in pachyonychia congenita / News in Context

Targeting gut-derived serotonin synthesis shows therapeutic potential in osteoporosis

Suven Life Sciences discloses novel 5-HT6 receptor ligands

Novel antibacterial compounds identified by Korean scientists

Pfizer presents new 5-HT2C receptor agonists with antiobesity potential

Aeolus begins second preclinical study of AEOL-10150 for acute radiation syndrome

Proximagen grants Upsher-Smith rights to tonabersat for epilepsy in North America

Clinical data disclosed on gabapentin enacarbil in restless legs syndrome

Roche discloses new therapeutics for type 2 diabetes

Oral torezolid phosphate safe in phase II trial in complicated skin/skin structure infection

Merck & Co. presents novel CGRP receptor antagonists

Astellas claims new inhibitors of Rho-associated protein kinase

Malaysian scientists disclose new rosamine analogues for cancer therapy

RXi and miRagen to collaborate on miRNA-based agents

MolMed's NGR-hTNF enters phase III in malignant pleural mesothelioma

Neurocrine begins second phase I clinical trial of VAT2 inhibitor NBI-98854 in Canada

Roche acquires Medingo and expands position in insulin delivery systems market

Critical Outcome Technologies provides update on HIV-1 integrase program

InterMune reports topline phase IIb danoprevir data in hepatitis C

Mersana and Teva Pharmaceutical collaborate on development of XMT-1107

Catalyst signs agreement with NIDA for phase IIb vigabatrin trial for cocaine addiction

Aeras and Crucell begin phase II trial of tuberculosis vaccine in HIV-infected adults

Adeona reports data on Zinthionein ZC in Alzheimer's disease and mild cognitive impairment

FDA announces phaseout dates for CFC-containing inhalers

Metabolex and Takeda enter research collaboration for biological products

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Fauci’s silence may put him in contempt of Congress
BioWorld
After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci,...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...